Novartis: FDA approves CAR-T therapy for pediatric use.
(CercleFinance.com) - Novartis's CAR-T therapy Kymriah has been approved by the US Food and Drug Administration for the treatment of young patients with leukemia.
The Swiss drugmaker said late Wednesday that the FDA has approved the suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia.
The approval concerns refractory forms of the disease or in second or later relapse.
Novartis has welcomed a "historic moment in cancer treatment."
Kymriah is a novel immuno-cellular therapy that uses a patient's own T cells to fight cancer. It is the first therapy based on gene transfer approved by the FDA.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The Swiss drugmaker said late Wednesday that the FDA has approved the suspension for intravenous infusion for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia.
The approval concerns refractory forms of the disease or in second or later relapse.
Novartis has welcomed a "historic moment in cancer treatment."
Kymriah is a novel immuno-cellular therapy that uses a patient's own T cells to fight cancer. It is the first therapy based on gene transfer approved by the FDA.
Copyright (c) 2017 CercleFinance.com. All rights reserved.